GMS (GMS) reported $1.33 billion in revenue for the quarter ended April 2025, representing a year-over-year decline of 5.6%. EPS of $1.29 for the same period compares to $1.93 a year ago. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. The reported revenue represents a surprise of +2.81% over the Zacks Consensus Estimate of $1.3 bill ...

For the quarter ended April 2025, Target (TGT) reported revenue of $23.85 billion, down 2.8% over the same period last year. EPS came in at $1.30, compared to $2.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $24.23 billion, representing a surprise of -1.58%. The company delivered an EPS surprise of -19.75%, with the consensus EPS estimate being $1.62.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Core Insights - Amphastar Pharmaceuticals reported revenue of $170.53 million for the quarter ended March 2025, reflecting a year-over-year decline of 0.8% [1] - The earnings per share (EPS) for the same period was $0.74, down from $1.04 a year ago, with a surprise of +12.12% compared to the consensus estimate of $0.66 [1] - The reported revenue was a surprise of -0.69% against the Zacks Consensus Estimate of $171.71 million [1] Revenue Breakdown - Primatene MIST generated net revenues of $29.05 million, exceeding the average estimate of $27.64 million, representing a year-over-year increase of +20.2% [4] - Glucagon reported net revenues of $20.84 million, slightly above the estimated $20.24 million, but showed a year-over-year decline of -27% [4] - Lidocaine achieved net revenues of $13.64 million, surpassing the average estimate of $13.15 million, with a year-over-year increase of +6.8% [4] - Epinephrine's net revenues were $18.59 million, above the estimated $18.21 million, but reflected a significant year-over-year decline of -28.8% [4] Stock Performance - Amphastar's shares returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Interparfums (IPAR) reported $338.82 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.6%. EPS of $1.32 for the same period compares to $1.27 a year ago.The reported revenue represents a surprise of +0.47% over the Zacks Consensus Estimate of $337.22 million. With the consensus EPS estimate being $1.13, the EPS surprise was +16.81%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Core Insights - Henry Schein reported $3.17 billion in revenue for Q1 2025, a slight year-over-year decline of 0.1% [1] - The EPS for the quarter was $1.15, up from $1.10 a year ago, indicating a positive trend in earnings [1] - The revenue fell short of the Zacks Consensus Estimate of $3.23 billion by 1.84%, while the EPS exceeded the consensus estimate of $1.11 by 3.60% [1] Revenue Performance - Geographic Revenue from International Dental Equipment was $197 million, below the average estimate of $209.20 million [4] - U.S. Distribution Revenue for Dental Equipment was $187 million, significantly lower than the estimated $232.79 million, reflecting a 25.4% decline year-over-year [4] - International Dental Merchandise revenue was $594 million, also below the estimate of $608.26 million [4] - U.S. Distribution Medical revenue was $1.03 billion, slightly above the estimate of $1.01 billion, showing a year-over-year increase of 1.6% [4] - International Dental revenue was $798 million, under the estimate of $824.47 million, with a year-over-year decline of 1.6% [4] - U.S. Distribution Dental Merchandise revenue was $591 million, exceeding the estimate of $569.68 million [4] - Global Specialty Products net sales were $367 million, slightly above the average estimate of $364.59 million [4] Stock Performance - Henry Schein's shares returned -0.3% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]